Imaging Alzheimer’s Disease with the ATN Framework and Beyond, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, attendees will learn about Alzheimer’s disease imaging biomarkers, the NIA-AA ATN research framework and how to use neuroimaging to enrich a clinical trial population. They will specifically discuss amyloid, tau, FDG and emerging PET markers for Alzheimer’s disease, along with structural, functional and advanced MRI techniques.

Xtalks Life Science Webinars

As neuroscientific and disease models evolve, so too do the methods used to interrogate the pathophysiologic processes driving AD specific neurodegeneration

The NIA-AA ATN research framework focuses on the diagnosis of Alzheimer’s disease (AD) with biomarkers in living persons, which shifts the definition of AD in living people from a symptomatic to a biological construct. The ATN framework is a method to classify and characterize disease presence/state through evaluation of β amyloid deposition (A), pathologic tau (T) and neurodegeneration (N). As neuroscientific and disease models evolve, so too do the methods used to interrogate the pathophysiologic processes driving AD specific neurodegeneration. This allows an expansion beyond the ATN framework by integrating vascular, iron and inflammation biomarkers to improve characterization of disease and likelihood of progression.

Join David Scott, PhD, Scientific Directo,r Kate Adamczuk, PhD, Senior Scientist, and Chris Conklin, PhD, MRI Scientist from Bioclinica in a live webinar on Wednesday, September 16, 2020 at 10:30am EDT (3:30pm BST/UK) in which they will discuss how multi-modal integration of molecular imaging, MRI and fluid biomarkers can provide a robust ability to accurately parse patients along the AD cascade to provide optimal classification and treatment strategies as well as therapeutic efficacy.

In the webinar, the speakers will present the best practices of amyloid PET imaging and the most recent developments in the tau PET imaging space, including quantitative and visual assessment paradigms per the latest FDA approval. Imaging of neurodegeneration and emerging biomarkers beyond N will also be examined. Techniques such as bi-compartment diffusion modeling, quantitative susceptibility mapping (QSM), arterial spin labeling (ASL) and breath-hold fMRI are capable of being deployed in a large-scale clinical trial setting and could aid patient selection and demonstrate therapeutic benefit. The presenters will also highlight emerging PET markers for α-synuclein, microgliosis and synaptic density and their role in further refining AD staging.

For more information or to register for this event, visit Imaging Alzheimer’s Disease with the ATN Framework and Beyond.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ayesha Rashid
Xtalks
+1 (416) 977-6555 x 272
Email >
Visit website